Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit.
ESMO Open
; 6(3): 100129, 2021 06.
Article
in En
| MEDLINE
| ID: mdl-33887687
With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and in so allowing our patients to achieve the best survival outcomes possible.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Chemoembolization, Therapeutic
/
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Humans
Language:
En
Journal:
ESMO Open
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: